

September 16, 2026

Grey Matters Announces an Increase to its Equity and Convertible Debenture Private Placement to CAD \$1.1 Million

NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES

VANCOUVER, British Columbia, Sept. 16, 2026 (GLOBE NEWSWIRE) -- Grey Matters Health Inc. (the "Company" or "Grey Matters") (CSE: GREY) (FRANKFURT: AGW0) (OTC: AGNPF), a Canadian healthcare company, is pleased to announce an increase and change to its non-brokered private placement offering (the "**Offering**") previously announced on August 20, 2026, with the first closing having occurred on September 9, 2026. The Offering was originally announced to consist of gross proceeds from the sale of equity units (an "**Equity Unit**") expected to be CAD \$500,000 and unsecured convertible debenture units (a "**Debenture Unit**") with gross proceeds expected to be CAD \$300,000, for an aggregate total of CAD \$800,000 from the Offering. The Company has increased the total aggregate gross proceeds of the Offering to CAD \$1.1 million with an additional CAD \$250,000 of Equity Units and \$250,000 of Debenture Units expected to be sold in the second tranche (the "**Second Tranche**").

On September 10, the Company announced the closing of the first tranche for gross proceeds totalling CAD \$600,000, consisting of CAD \$285,000 from the sale of 712,500 Equity Units and CAD \$315,000 from the sale of Debenture Units. The private placement of Equity Units and Debenture Units is collectively referred to as the offering (the "Offering"). Following the expected closing of the Second Tranche, the aggregate gross proceeds of CAD \$1.1 million from the Offering would consist of CAD \$535,000 from Equity Units and CAD \$565,000 from Debenture Units.

Each Equity Unit, at an issue price of CAD \$0.40, consists of one Class A common share in the capital of the Company (a "**Common Share**") and one Common Share purchase warrant (a "**Warrant**"). Each Warrant entitles the holder to acquire one Common Share (a "**Warrant Share**") at an exercise price of CAD \$0.60 (the "**Exercise Price**") per Warrant Share for a period of 36 months from the issuance date (the "**Expiry Date**").

Each Debenture Unit consists of one debenture (a "**Convertible Debenture**") in the principal amount of CAD \$1,000 and 2,198 common share purchase warrants (a "**Debenture Warrant**"). The Convertible Debentures carry interest at a rate of 10% per annum from the closing date, payable semi-annually in arrears until the maturity date, which will be 24 months from the closing date of the Convertible Debentures or the conversion date of the Debentures. The outstanding principal and interest can be converted, at the option of the Convertible Debenture holder, into Common Share at a fixed price of CAD \$0.455 per Common Share on or before the maturity date of the Convertible Debenture. The Company may from time to time, in its sole discretion, prepay all or a part of the principal amount and

accrued interest without penalty. Each Debenture Warrant entitles the holder to acquire one Common Share (a “**Debenture Warrant Share**”) at an exercise price of CAD \$0.55 per Debenture Warrant Share for a period of 36 months from the date of issuance.

The Company may pay cash finder’s fees and finders warrants to eligible finders for investors introduced to the Company by the eligible finder in regards to the Second Tranche of the Offering.

The Company will use the proceeds of the Offering to advance its Alzheimer’s Disease program towards the opening of U.S. brain-specific neuroimaging clinic, general and administrative expenses, and for working capital purposes.

The Company expects to close the second and final tranche of the Offering on or before September 21, 2026.

The securities issued and issuable, described in this and the previous news releases from August 20, 2026 and September 10, 2026, will be subject to a statutory hold period of four months plus a day from the date of issuance in accordance with applicable Canadian securities legislation.

The securities have not been and will not be registered under the United States Securities Act of 1933, as amended (the “U.S. Securities Act”), or any state securities laws, and may not be offered or sold within the United States or to, or for the account or benefit of, “U.S. persons” (as such term is defined in Regulation S under the U.S. Securities Act) absent registration under the U.S. Securities Act and applicable state securities laws, or an exemption from such registration.

For more information please contact:

Christopher J. Moreau
CEO
Grey Matters Health Inc.
604.398.4175 Ext 701

cjmoreau@greymatters-health.com
info@greymatters-health.com
www.greymatters-health.com

About Grey Matters

Grey Matters is a Canadian healthcare company focused on the provision of brain dedicated PET scanning services through a planned network of new neuroimaging clinics in the U.S. for the early-stage detection of Alzheimer’s Disease and other forms of neurodegenerative diseases, including frontotemporal dementia, Parkinson’s, and Lewy body dementia, and will additionally offer other select neuro-oncology imaging applications too.

Neither the Canadian Securities Exchange nor its Market Regulator (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.

CAUTIONARY DISCLAIMER STATEMENT: This news release contains forward-looking

statements that are not historical facts. Forward-looking statements are often identified by terms such as “will”, “may”, “should”, “anticipate”, “expects” and similar expressions. All statements other than statements of historical fact, included in this release are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the Company’s expectations include the failure to satisfy the conditions of the relevant securities exchange(s) and other risks detailed from time to time in the filings made by the Company with securities regulations. The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company. The reader is cautioned not to place undue reliance on any forward-looking information. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company will update or revise publicly any of the included forward-looking statements as expressly required by applicable law.



Source: Grey Matters Health Inc.